Genome Therapeutics Corporation

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Genome Therapeutics Corp. was one of the earliest biotech companies. It was founded in 1961 by Dr.Orrie M. Friedman under the name Collaborative Research Inc.[1] Under the leadership of Helen Donis-Keller and using internal funds, the company produced one of the first linkage maps of the whole human genome in the mid 1980s.[2][3]

The name was later changed its name to Genome Therapeutics and, in 1994, produced the first commercial genome sequence,[2] that of Helicobacter pylori, the pathogen responsible for peptic ulcers. The rights to the genome were sold to Astra AB of Sweden for $22 million and a similar deal struck with Schering-Plough.[2] In addition to infectious agents, it also worked on heritable diseases including asthma [4]

In 2004 Genome Therapeutics changed its name to Oscient Pharmaceuticals[5] and its sequencing division joined with Agencourt Bioscience. The latter spun out Agencourt Personal Genomics which was acquired by ABI for $120 million in 2007.[6]